This study is testing rosuvastatin, a medication commonly used for high cholesterol, to see if it can help people with cirrhosis (scarring of the liver). We want to understand if rosuvastatin is safe and effective in improving liver health over 96 weeks. You might be able to join if you are between 18 and 75 years old and have cirrhosis caused by conditions like nonalcoholic steatohepatitis, alcohol-related liver disease, or treated viral hepatitis. The main goal is to see how much liver stiffness changes after treatment, which is a way to measure liver health. The study is currently recruiting 256 participants.

Study design

This is a randomized, double-blind, placebo-controlled Phase 2 study, meaning participants will be randomly assigned to receive either rosuvastatin or a placebo (an inactive substance) without knowing which they are getting. The study plans to enroll 256 participants.

What's involved

You will first have a 4-week period where you take rosuvastatin to check for safety and how well you can take the medication. After that, you will continue with your assigned treatment (rosuvastatin or placebo) for 96 weeks.

Compensation

Not stated in the trial record.

Follow-up

Participants will be followed for 96 weeks after starting their assigned treatment.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.